Loxo Oncology is dedicated to developing highly selective medicines for patients with genetically defined cancers. The Company bases its approach on two scientific trends: the increasing use of genetic testing in cancer clinical medicine and improving chemistry approaches to building highly selective inhibitors against single targets in the cancer cell. Loxo Oncology is developing a pipeline of highly selective drugs that inhibit oncogenic drivers in cancer.

Type
Public
HQ
Stamford, US
Founded
2013
Size (employees)
47 (est)+57%
Loxo Oncology was founded in 2013 and is headquartered in Stamford, US
Report incorrect company information

Key People/Management at Loxo Oncology

Josh Bilenker

Josh Bilenker

Founder, President & CEO
Nisha Nanda

Nisha Nanda

VP of Development Strategy
Jacob Van Naarden

Jacob Van Naarden

Chief Business Officer
Jennifer Burstein

Jennifer Burstein

VP of Finance

Loxo Oncology Office Locations

Loxo Oncology has offices in Stamford and South San Francisco
Stamford, US (HQ)
281 Tresser Blvd
South San Francisco, US
520 400 Oyster Point Blvd
Show all (2)
Report incorrect company information

Loxo Oncology Financials and Metrics

Loxo Oncology Financials

USD

Net income (Q1, 2018)

(3.6 m)

EBIT (Q1, 2018)

(5.8 m)

Market capitalization (22-Jun-2018)

5.5 b

Closing share price (22-Jun-2018)

183.8

Cash (31-Mar-2018)

103.8 m
Loxo Oncology's current market capitalization is $5.5 b.
Annual
USDFY, 2014FY, 2015FY, 2016

General and administrative expense

583 k10.5 m14.9 m

R&D expense

323 k14 m58.3 m

Operating expense total

906 k24.5 m73.2 m

Net Income

(10.3 m)(35.9 m)(72.4 m)
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

General and administrative expense

2.4 m2.6 m3.4 m3.8 m3.7 m4.8 m6.5 m12.2 m

R&D expense

2.8 m3.4 m8.4 m12.3 m14.2 m20.2 m24.4 m32 m

Operating expense total

5.2 m5.9 m11.8 m16.1 m17.9 m24.9 m30.9 m44.2 m

EBIT

(5.8 m)
Annual
USDFY, 2014FY, 2015FY, 2016

Cash

43.9 m68.2 m30.4 m

Accounts Receivable

1.1 b

Current Assets

107.8 m156.6 m141.8 m

PP&E

12 k88 k248 k
Quarterly
USDQ1, 2017Q2, 2017Q1, 2018

Cash

48.5 m260.3 m103.8 m

Current Assets

244.4 m471.4 m720.6 m

PP&E

328 k364 k1.6 m

Total Assets

249.4 m472.4 m748.6 m
Annual
USDFY, 2014FY, 2015FY, 2016

Net Income

(20.7 m)(35.9 m)(72.4 m)

Depreciation and Amortization

1 k17 k77 k

Accounts Payable

18 k30 k792 k

Cash From Operating Activities

(2.8 m)(30.2 m)(51.3 m)
Quarterly
USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Net Income

(8.1 m)(8.8 m)(11.6 m)(15.9 m)(17.7 m)(24.5 m)(54.9 m)(3.6 m)

Depreciation and Amortization

21 k48 k80 k

Accounts Payable

207 k285 k415 k731 k758 k677 k1 m192 k1.1 m1.8 m

Cash From Operating Activities

(26.7 m)(50.5 m)109.8 m
USDY, 2018

Financial Leverage

1.9 x
Show all financial metrics
Report incorrect company information

Loxo Oncology Online and Social Media Presence

Embed Graph
Report incorrect company information

Loxo Oncology News and Updates

Loxo Oncology posts improved results for newest cancer drug

CHICAGO, June 2 (Reuters) - An experimental cancer drug from Loxo Oncology performed even better in patients with a rare mutation of the RET gene than previously reported, according to updated results from an early stage clinical trial presented on Saturday.
Report incorrect company information